-
Gait abnormalities relate to increased extracellular water in the substantia nigra in Parkinson’s disease patients
-
Gait Analysis in Normal Pressure Hydrocephalus: a Meta-Analysis
-
GAIT ANALYSIS IN PARKINSONIAN SUBJECTS WITH PISA SYNDROME SUBJECTED TO TREATMENT WITH BOTULINUM TOXIN
-
Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status
-
Gait and Balance Characteristics in Atypical Parkinsonian Syndromes
-
Gait ataxia and Autonomic dysfunction as early signs of Creutzfeldt-Jakob Disease: A Case Report
-
Gait Characteristics from Daily Life Increase Ability to Predict Future Falls in People with Parkinson’s Disease
-
Gait declines faster over time in people with Parkinson’s disease converting to a freezing of gait phenotype
-
Gait under unsupervised, but not supervised conditions, differentiates between Parkinson disease with and without fatigue
-
GDNF Gene Therapy for Parkinson’s Disease (PD): Preliminary Safety and Clinical Findings from a Phase Ib Study
-
Gender Identity and Treatment Response in Patients with Functional Tic-Like Behavior
-
Gender-related sexual dysfunction in Parkinson disease: Clinical data of a hospital cohort in Tunisia
-
Gene and variant curation of Parkinson’s disease genes by an authoritative expert panel
-
Gene Expression Quantification to Assess Frataxin Replacement Therapies in Friedreich’s Ataxia
-
Genetic contribution to domain specific cognitive decline
-
Genetic correlation and potential causal relationship between inflammatory bowel disease and Parkinson’s disease
-
Genetic determinants of early motor progression in Parkinson’s cohorts
-
Genetic landscape of dystonia in Asian Indian patients
-
Genetic stratification of motor and quality of life outcomes in Parkinson’s disease in the EARLYSTIM study
-
Genetics Of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) : Genetics of Juvenile, Young and Early Onset Parkinson’s Disease
-
Genome-wide association study of Aβ, t-tau and p-tau in CSF in Parkinson’s disease
-
Genome-wide meta-analysis of Parkinson’s disease identifies a novel chromosomal 22 locus: findings from the COURAGE-PD consortium
-
Geographic and Financial Trends in the Utilization of Deep Brain Stimulation in the Medicare Population from 2013-2019
-
Gerstmann-Sträussler-Scheinker disease presenting as dystonia
-
Gerstmann-Straussler-Scheinker Syndrome Manifesting Levodopa-Responsive Parkinsonism, Levodopa-Induced Dyskinesia, and Abnormal DaT-SPECT
-
Giant symptomatic capillary telangiectasia: uncommon cause of cerebellar ataxia
-
GLA-associated early-onset Parkinson’s disease: the mimicry between Fabry disease and parkinsonisms
-
Glial neurotrophic factor as an early diagnostic marker in Parkinson’s disease
-
Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
-
GLUT1 Deficiency Syndrome with Novel mutation responsive to GPi DBS
-
GNAO1 related disorders: a clinical, genetic, and therapeutic update
-
Goals for Improvement in Essential Tremor Patients Following Focused Ultrasound VIM Thalamotomy
-
Gold and silver nanoparticle-based Localized Surface Plasmon Resonance Sensor (LSPR) for the detection of histidine as a potential biomarker in Parkinson’s Disease.
-
GP2: Growing a research community in the Parkinson’s disease genetics field through training and networking
-
GPi-DBS induced brain metabolic activation in cervical dystonia
-
Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes
-
Gray matter volumetry, cortical thickness and cognitive performance in treated Parkinson’s disease with REM sleep behavior disorder symptomatology
-
Grey and white matter brain structural alterations in patients with Essential Tremor plus dystonic soft signs
-
GRIN2D is a cause of autosomal dominant form of Parkinson’s disease
-
GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease
-
Gut dysbiosis in patients with dementia with Lewy bodies
2022 International Congress
September 15-18, 2022. Madrid, Spain.